DARE Dare Bioscience: רווח נקי למניה ב-12 החודשים האחרונים

Despite the patent protection of hydrogels and the success of Xaciato, Dare Bioscience, Inc. (DARE) continues to experience volatility. The annual net income per share growth rate (ttm) visualizes this gap, where the level of -83.00 represents the current value. US centers creating scarce treatment methods provide stability, while bioethical development standards and strict environmental resource disposal controls restore confidence.

To assess the fundamental stability of Dare Bioscience, Inc. (DARE), investors must analyze the year-over-year dynamics of net earnings per share. This chart of relative EPS YoY TTM changes visualizes profit growth rates over the last twelve months, allowing for the tracking of commercial deal effectiveness and the impact of Big Pharma sponsorship on the final profitability of the company's R&D model.